EGFR and non-small cell lung carcinoma: The ongoing NeoADAURA trial (NCT04351555) is evaluating neoadjuvant osimertinib with or without chemotherapy versus chemotherapy with a placebo prior to surgical resection in patients with stage II–IIIB N2 EGFR mutant + NSCLC, with MPR rates as the primary endpoint [79].